Integrated Filing — IndAS



General information about company

Scrip Code 531768
NSE Symbol POLYMED
MSEI Symbol NA
ISIN INE205C01021
Name of company POLY MEDICURE LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2026
Date of end of financial year 31-03-2027
Date of board meeting when results were approved 05-11-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 29-10-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Second quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Unaudited
Segment Reporting Single segment
Description of single segment Mnaufacturing of Medical Devices
Start date and time of board meeting 05-11-2026   11:30:00
End date and time of board meeting 05-11-2026   14:00:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 05-11-2023
Indicate Company website link for updated RPT policy of the Company https://investors.polymedicure.com/wp-content/uploads/2026/08/policy-on-dealing-with-related-party-transactions.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
NA



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations 48,827.62 91,937.57
Other income 2,043.66 4,907.30
Total income 50,871.28 96,844.87
2 Expenses
(a) Cost of materials consumed 18,226.92 33,501.52
(b) Purchases of stock-in-trade 85.66 262.78
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (3,115.97) (6,288.12)
(d) Employee benefit expense 9,565.15 18,455.95
(e) Finance costs 399.72 838.18
(f) Depreciation, depletion and amortisation expense 2,725.90 5,372.90
(f) Other Expenses
1 Research and Deveolpment Expenses 835.67 1,623.68
2 Other Expenses 9,840.71 18,906.52
Total other expenses 10,676.38 20,530.20
Total expenses 38,563.76 72,673.41
3 Total profit before exceptional items and tax 12,307.52 24,171.46
4 Exceptional items 0.00 0.00
5 Total profit before tax 12,307.52 24,171.46
6 Tax expense
7 Current tax 2,739.65 5,246.39
8 Deferred tax 365.37 910.24
9 Total tax expenses 3,105.02 6,156.63
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 9,202.50 18,014.83
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 9,202.50 18,014.83
17 Other comprehensive income net of taxes 68.15 0.10
18 Total Comprehensive Income for the period 9,270.65 18,014.93
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 5,068.07 5,068.07
Face value of equity share capital 5 5
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 9.08 17.77
Diluted earnings (loss) per share from continuing operations 9.07 17.75
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 9.08 17.77
Diluted earnings (loss) per share from continuing and discontinued operations 9.07 17.75
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2026
Date of end of reporting period 30-09-2026
Whether results are audited or unaudited Unaudited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 1,24,895.37
Capital work-in-progress 10,983.28
Investment property 0.00
Goodwill 0.00
Other intangible assets 1,304.89
Intangible assets under development 612.47
Biological assets other than bearer plants 0.00
Investments accounted for using equity method 53,061.49
Non-current financial assets
Non-current investments 1,263.51
Trade receivables, non-current 0.00
Loans, non-current 0.00
Other non-current financial assets
1 Right of use assets 174.90
2 Other Financal Assets 1,840.34
3 Other non-current assets 6,337.64
Total of other non-current financial assets 8,352.88
Total non-current financial assets 9,616.39
Deferred tax assets (net) 0.00
Other non-current assets
Total of other non-current assets
Total non-current assets 2,00,473.89
2 Current assets
Inventories 34,586.71
Current financial asset
Current investments 71,806.55
Trade receivables, current 47,431.26
Cash and cash equivalents 769.70
Bank balance other than cash and cash equivalents 3,992.98
Loans, current 496.43
Other current financial assets
Total of other current financial assets 4,095.90
Total current financial assets 1,28,592.82
Current tax assets (net) 12,071.49
Other current assets
Total of other current assets
Total current assets 1,75,251.02
3 Non-current assets classified as held for sale 0.00
4 Regulatory deferral account debit balances and related deferred tax Assets 0.00
Total assets 3,75,724.91
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 5,068.07
Other equity 3,15,104.42
Total equity attributable to owners of parent 3,20,172.49
Non controlling interest
Total equity 3,20,172.49
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 21.51
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0.00
Total Trade payable 0.00
Other non-current financial liabilities
1 lease liablites 62.02
2 othert financial liablities 71.49
Total of other non-current financial liabilities 133.51
Total non-current financial liabilities 155.02
Provisions, non-current 1,430.65
Deferred tax liabilities (net) 6,706.23
Deferred government grants, Non-current 60.52
Other non-current liabilities
Total of other non-current liabilities
Total non-current liabilities 8,352.42
Current liabilities
Current financial liabilities
Borrowings, current 28,242.21
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 975.49
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 8,599.39
Total Trade payable 9,574.88
Other current financial liabilities
1 lease liablities 128.66
2 other financial liablities 6,381.15
Total of other current financial liabilities 6,509.81
Total current financial liabilities 44,326.90
Other current liabilities 1,661.55
1 Other current liabilities 1,661.55
Total of other current liabilities 1,661.55
Provisions, current 45.71
Current tax liabilities (Net) 1,165.84
Deferred government grants, Current
Total current liabilities 47,200.00
3 Liabilities directly associated with assets in disposal group classified as held for sale
4 Regulatory deferral account credit balances and related deferred tax liability
Total liabilities 55,552.42
Total equity and liabilites 3,75,724.91
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-07-2026 01-04-2026
Date of end of reporting period 30-09-2026 30-09-2026
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Remeasurements of defined benefit obligations 91.08 0.14
Total Amount of items that will not be reclassified to profit and loss 91.08 0.14
2 Income tax relating to items that will not be reclassified to profit or loss 22.93 0.04
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss 0.00 0.00
5 Total Other comprehensive income 68.15 0.10



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2026
B Date of end of reporting period 30-09-2026
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Standalone
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 24,171.46
Adjustments for reconcile profit (loss)
Adjustments for finance costs 838.18
Adjustments for decrease (increase) in inventories (6,452.37)
Adjustments for decrease (increase) in trade receivables, current (4,326.12)
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets (3,195.37)
Adjustments for decrease (increase) in other non-current assets (308.30)
Adjustments for other financial assets, non-current (19.54)
Adjustments for other financial assets, current 264.22
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current 1,211.34
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities (960.41)
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 5,372.90
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current 21.92
Adjustments for provisions, non-current 10.04
Adjustments for other financial liabilities, current 931.55
Adjustments for other financial liabilities, non-current (5.82)
Adjustments for unrealised foreign exchange losses gains 1,006.31
Adjustments for dividend income 318.95
Adjustments for interest income 250.40
Adjustments for share-based payments 431.93
Adjustments for fair value losses (gains) (2,748.69)
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow 0.00
Other adjustments to reconcile profit (loss) 0.00
Other adjustments for non-cash items (152.17)
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) (8,649.75)
Net cash flows from (used in) operations 15,521.71
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 4,638.61
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities 10,883.10
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 2,741.00
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 0.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 5.66
Purchase of property, plant and equipment 10,788.01
Proceeds from sales of investment property 0.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 0.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 3,642.28
Purchase of other long-term assets 347.46
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 139.18
Interest received 167.52
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) investing activities (9,921.83)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 0.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 1.98
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 3,386.52
Repayments of borrowings 0.00
Payments of lease liabilities 140.28
Dividends paid 3,229.13
Interest paid 804.47
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) financing activities (785.38)
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 175.89
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0.00
Net increase (decrease) in cash and cash equivalents 175.89
Cash and cash equivalents cash flow statement at beginning of period 593.81
Cash and cash equivalents cash flow statement at end of period 769.70





Amount in (Lakhs)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)

Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 POLY MEDICURE LIMITED VITROMED HEALTHCARE Entity with Joint Control or significant influence over entity(Directors of Poly Medicure Limited are also the partner and/or relative of partners of Vitromed Healthcare) Sale of goods or services 16,017.00 NA 2,442.90 0.00 1,085.02
2 POLY MEDICURE LIMITED ULTRA FOR MEDICAL PRODUCTS, EGYPT Associates(POLY MEDICURE LIMITED holds 23% shares of Ultra for Medical Products, Egypt) Sale of goods or services 16,017.00 NA 200.92 331.12 189.15
3 POLY MEDICURE LIMITED JAI POLYPAN PVT. LTD. PROMOTER GROUP Any other transaction LEASE NA 0.71 0.14 0.00
4 POLY MEDICURE LIMITED JAI CHAND LAL HULASI DEVI BAID CHARITABLE TRUST Other Related party transaction(This NGO is managed and controlled by the Promoters ) Any other transaction Donation NA 119.64 0.00 0.00
5 POLY MEDICURE LIMITED RISHI BAID Promoters(Joint Managing Director of Poly Medicure Limited) Remuneration NA 955.15 727.62 653.72
6 POLY MEDICURE LIMITED NARESH VIJAYVERGIYA Key Managerial Person of Entity and Parent(CFO of Poly Medicure Limited) Remuneration NA 64.12 19.73 5.62
7 POLY MEDICURE LIMITED AVINASH CHANDRA Key Managerial Person of Entity and Parent(Company Secretary & Compliance Officer of Poly Medicure Limited) Remuneration NA 10.81 2.19 1.54
8 POLY MEDICURE LIMITED DHRUV BAID Promoters group(Son of Himanshu Baid, Managing Director of the Company) Remuneration NA 88.30 14.32 14.64
9 POLY MEDICURE LIMITED AARYAMAN BAID Promoters group(Son of Himanshu Baid, Managing Director of the Company) Remuneration NA 63.79 6.45 6.15
10 POLY MEDICURE LIMITED ARHAM BAID Promoters group(Son of Rishi Baid, Joint Managing Director of the Company) Remuneration NA 63.79 6.45 6.15
11 POLY MEDICURE LIMITED JUGAL KISHORE BAID Promoters(Non Executive & Non Independent Director of Poly Medicure Limited) Remuneration NA 11.50 16.20 9.00
12 POLY MEDICURE LIMITED RAVI PRAKASH Key Managerial Person of Entity and Parent(Company Secretary & Compliance Officer of Poly Medicure Limited) Remuneration NA 8.12 1.72 0.00
13 POLY MEDICURE LIMITED DEVENDRA RAJ MEHTA Other related party (He is the Chairman and Non Executive Non-Independent director of the company) Remuneration NA 14.00 16.20 9.00
14 POLY MEDICURE LIMITED AMIT KHOSLA Other related party (He is the Independent director of the company) Remuneration NA 13.50 16.20 9.00
15 POLY MEDICURE LIMITED SONAL MATTOO Other related party (She is the Independent director of the company) Remuneration NA 13.50 16.20 9.00
16 POLY MEDICURE LIMITED ALESSANDRO BALBONI Other Related Party(Non executive & Non Independent Director of Poly Medicure Limited) Remuneration NA 144.78 30.26 32.87
17 POLY MEDICURE LIMITED HIMANSHU BAID Promoters(He is the Managing Director of the Company) Remuneration NA 980.73 726.86 653.72
18 POLY MEDICURE LIMITED VISHAL BAID Promoters(He is the Executive Director of the Company, Brother of the Himanshu Baid and Rishi Baid and also the son of Jugal Kishore Baid and Mukulika BAID) Remuneration NA 526.85 376.25 331.23
19 POLY MEDICURE LIMITED VITROMED HEALTHCARE Entity with Joint Control or significant influence over entity(Directors of Poly Medicure Limited are also the partner and/or relative of partners of Vitromed Healthcare) Purchase of goods or services NA 13.61 0.00 1.02
20 POLY MEDICURE LIMITED VITROMED HEALTHCARE Entity with Joint Control or significant influence over entity(Directors of Poly Medicure Limited are also the partner and/or relative of partners of Vitromed Healthcare) Any other transaction LEASE NA 0.10 0.00 0.10
21 POLY MEDICURE LIMITED VITROMED HEALTHCARE Entity with Joint Control or significant influence over entity(Directors of Poly Medicure Limited are also the partner and/or relative of partners of Vitromed Healthcare) Any other transaction Receving of Service 16,017.00 NA 4,610.21 0.00 1,001.49
22 POLY MEDICURE LIMITED AMBRISH MITHAL Other related party (He is the Independent director of the company) Remuneration NA 11.00 16.20 9.00
23 POLY MEDICURE LIMITED VIMAL BHANDARI Other related party (He is the Independent director of the company) Remuneration NA 12.50 16.20 9.00
24 POLY MEDICURE LIMITED VISHAL GUPTA Other related party (He is the Independent director of the company) Remuneration NA 10.00 16.20 9.00
25 POLY MEDICURE LIMITED PANKAJ KUMAR GUPTA Other related party (He is the Executive director of the company) Remuneration NA 48.82 31.32 3.51
Total value of transaction during the reporting period 10,429.35